Navigation Links
Triple Revenue Growth Rate for Transplant Molecular Testing, According to Report
Date:5/3/2017

ROCKVILLE, Md., May 3, 2017 /PRNewswire/ -- Kalorama Information notes that transplant diagnostics is seeing revenue growth of nine percent next year and this is projected to continue to 2021. Successful solid organ and hematopoietic stem cell (HSCT) or bone marrow transplants require histocompatibility between the recipient and donor. Molecular testing technologies are well-suited for this task. This according to a new report from healthcare-only market research publisher Kalorama Information. The various PCR-based methodologies, Sanger sequencing and NGS used to type HLA alleles in low to high resolution in order to match donors and recipients for solid organ and hematopoietic stem cell (HSCT) or bone marrow transplants; post-transplant monitoring including for transplant rejection is an ancillary testing area. The finding was made in the firm's report Transplant Matching Molecular Diagnostics.

"Molecular is not ubiquitous, as some forecasters – including us- may have thought a decade ago," said Bruce Carlson, Publisher of Kalorama Information. "It performs well in areas where it is set apart from other technologies. HLA is a value-add area for molecular, and you see that in the growth rate."

The report said the global market for molecular transplant diagnostics is estimated at over three hundred million at an average annual rate of growth of 9%. Over allogenic 9,000 HSCTs and approximately 30,000 solid organ transplants are performed in the United States each year. The large size of the U.S. market is sustained by demand for high resolution molecular HLA typing, including sequencing-based methods. More than 30,000 solid organ transplants and around 18,000 HSCTs are performed each year in Europe. Transplant volumes continue to grow at a faster pace in Europe than in the United States as Eastern European countries and other less mature markets perform more solid organ transplants and HSCTs. This is driving sales of test products. 

The United States is the largest market for leading molecular transplant diagnostics companies Thermo Fisher Scientific, CareDx (Olerup brand), and Immucor (LIFECODES brand).

Kalorama's report, Transplant Matching Molecular Diagnostics Market provides:  

  • Global Market Forecast to 2021
  • Global Molecular Transplant Procedure Volumes, 2016 to 2021
  • Global Market Share by Vendor

The report can be found at:  https://www.kaloramainformation.com/Transplant-Matching-Molecular- 10819543/

About Kalorama Information

Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. Reports can be purchased through Kalorama's website and are also available on www.marketresearch.com and www.profound.com.  

We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog on our company website.  

Please link any media or news references to our reports or data to http://www.kaloramainformation.com/.

Press Contact:
Bruce Carlson
212 807 2262
bcarlson@marketresearch.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/triple-revenue-growth-rate-for-transplant-molecular-testing-according-to-report-300450452.html


'/>"/>
SOURCE Kalorama Information
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. CASI Pharmaceuticals Reports On Enrollment Status Of ENMD-2076 Phase 2 Study In Triple-Negative Breast Cancer
2. Landmark Study Published Today in The Lancet Shows Clear Myeloma Survival Benefit with Triple Drug Combination
3. Theravance Biopharma Highlights Initiation of Phase 3 Study of the Closed Triple in Patients with Asthma by GlaxoSmithKline and Innoviva
4. Theravance Biopharma Highlights Filing of U.S. New Drug Application for the Closed Triple in COPD by GlaxoSmithKline and Innoviva
5. North American Cannabis Holdings and Puration Prepare for Legal Marijuana Sector to Potentially Triple from $7 Billion to $22 Billion After Votes Today are Tabulated
6. Morphotek Announces Collaboration with Mayo Clinic to Apply Its Folate Receptor Alpha Diagnostic Assays in a Phase II Clinical Trial in Triple-Negative Breast Cancer
7. Data On Anti-Tumor Activity Of ENMD-2076 In Triple Negative Breast Cancer Animal Models Presented In Poster Session At AACR-NCI-EORTC International Conference
8. goBalto Triples Sites Managed, Further Reinforcing Market Leadership Position
9. India Coronary Stent Market to be Tripled by 2021
10. TapImmune Appoints Patrick D. Yeramian, MD, Consulting Medical Director to Lead Phase II Clinical Trials in Triple Negative Breast and HER2/neu Breast Cancer
11. Top 10 Health Care Trends Report Finds Opportunities to Achieve "Triple Aim"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... Calif. , Oct. 11, 2017  BioPharmX Corporation ... scientific team that developed an innovative way to use ... of the delivery of new drugs. ... Fall Clinical Dermatology Conference will show how researchers from ... Hospital, Harvard Medical School used a suite of imaging ...
(Date:10/11/2017)...  True Health, a leader in integrated diagnostics ... National Breast Cancer Awareness month to educate doctors ... Research recently published in ... than 10 million American women are at significant ... BRCA2 and have not had testing. These mutations can ...
(Date:10/10/2017)... ORANGE COUNTY, Calif. , Oct. 10, 2017  NDS received ... Mobile  — a medical-grade battery-powered display stand specifically designed for ... aims to transform technology into a clinical solution to support the ... costs. Innovative Design ... NDS ZeroWire Mobile Wireless Solution ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... ... IsoComforter, Inc. ( https://isocomforter.com ), one of the Nation’s premier ... of the shoulder pad. The shoulder pad provides optimal support and full contact ... using cold therapy. By utilizing ice and water that is circulated from an insulated ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...
(Date:10/12/2017)... ... ... Leading pediatric oncology experts at Children’s National Health System will ... the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by Jeffrey ... Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of the Division ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... (HLA), the nation's first interactive health literacy software tool, and the Cancer Patient ... aspects of cancer patient education, today announce a new strategic alliance. , ...
(Date:10/12/2017)... ... October 12, 2017 , ... Farm Forward joins ... other leading institutions in announcing the launch of the Leadership Circle , ... animals are raised for food. , Founding members of the Leadership Circle also ...
Breaking Medicine News(10 mins):